Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

SPRY

ARS Pharmaceuticals Inc

Nov 28 • 03:26PM ET

9.54

-0.03 -0.31 %

Healthcare • Biotechnology • USA • NASD

Peers: ALNY IONS RNA ARWR SRPT NBIX ENTA VRTX RARE ASND

| Held by: XBI VTI IWM VXF IWO IBB SCHA VTWO USVM SMLF

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.81	Insider Own	39.58%	Shs Outstand	98.84M	Perf Week	41.75%
Market Cap	943.02M	Forward P/E	-	EPS next Y	-1.29	Insider Trans	-2.66%	Shs Float	59.72M	Perf Month	6.24%
Enterprise Value	752.57M	PEG	-	EPS next Q	-0.42	Inst Own	64.44%	Short Float	33.72%	Perf Quarter	-17.90%
Income	-80.04M	P/S	6.61	EPS this Y	-2241.67%	Inst Trans	2.10%	Short Ratio	7.61	Perf Half Y	-33.89%
Sales	142.77M	P/B	6.39	EPS next Y	24.71%	ROA	-27.11%	Short Interest	20.14M	Perf YTD	-9.57%
Book/sh	1.49	P/C	3.27	EPS next 5Y	-	ROE	-45.92%	52W High	18.90 -49.52%	Perf Year	-30.42%
Cash/sh	2.92	P/FCF	-	EPS past 3/5Y	- -	ROIC	-32.69%	52W Low	6.66 43.24%	Perf 3Y	51.91%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	152.98% -	Gross Margin	89.29%	Volatility	9.80% 9.06%	Perf 5Y	-
Dividend TTM	-	EV/Sales	5.27	EPS Y/Y TTM	-59.70%	Oper. Margin	-63.59%	ATR (14)	0.69	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.51	Sales Y/Y TTM	5459.66%	Profit Margin	-56.06%	RSI (14)	57.57	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.66	EPS Q/Q	-162.66%	SMA20	13.68%	Beta	0.81	Target Price	28.67
Payout	0.00%	Debt/Eq	0.66	Sales Q/Q	1471.62%	SMA50	1.70%	Rel Volume	0.32	Prev Close	9.57
Employees	160	LT Debt/Eq	0.66	Earnings	Nov 10 BMO	SMA200	-25.94%	Avg Volume	2.65M	Price	9.54
IPO	Dec 04, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-14.59% 13.35%	Trades		Volume	848,573	Change	-0.31%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-25	Resumed	Roth Capital	Buy	$30
Sep-04-25	Initiated	Roth Capital	Buy	$40
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$30
Feb-10-25	Initiated	Oppenheimer	Outperform	$40
Aug-20-24	Initiated	Cantor Fitzgerald	Overweight
Aug-13-24	Upgrade	Raymond James	Outperform → Strong Buy	$18 → $22
Aug-12-24	Reiterated	Leerink Partners	Outperform	$19 → $20
Jul-25-24	Initiated	Raymond James	Outperform	$18
Mar-05-24	Upgrade	Leerink Partners	Market Perform → Outperform	$6 → $18
Feb-20-24	Upgrade	William Blair	Mkt Perform → Outperform
Sep-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Jan-31-23	Initiated	Wedbush	Outperform	$10
Jan-03-23	Initiated	William Blair	Outperform	$17
Dec-13-22	Initiated	SVB Leerink	Outperform	$14

Show Previous Ratings

Nov-26-25 08:00AM	ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-10-25 04:01PM	ARS Pharmaceuticals Inc (SPRY) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
07:05AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
06:00AM	ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy (epinephrine nasal spray) (GlobeNewswire)
Nov-07-25 07:19AM	ARS Pharmaceuticals Inc (SPRY) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com) +7.99%
09:10AM	Loading…
Nov-06-25 09:10AM	Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -9.45%
Nov-05-25 09:15AM	NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-04-25 09:35AM	DraftKings, Flutter downgraded: Wall Street's top analyst calls (The Fly)
08:00AM	ARS Pharma Launches Get neffy on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray) (GlobeNewswire)
Nov-03-25 02:23PM	UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results (GlobeNewswire)
07:45AM	ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
Oct-08-25 08:00AM	ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy (epinephrine nasal spray) (GlobeNewswire) +7.55%
Sep-29-25 04:05PM	ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy (GlobeNewswire)
Sep-19-25 08:00AM	neffy (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
11:44AM	Loading…
Sep-17-25 11:44AM	ARS Pharmaceuticals, Inc. (SPRY): A Bull Case Theory (Insider Monkey)
Sep-09-25 08:11AM	ARS Pharmaceuticals announces real-world evidence on neffy effectiveness (TipRanks)
Sep-08-25 08:00AM	Real-World Evidence Supports Clinical Effectiveness of neffy (epinephrine nasal spray) in Patients Experiencing Anaphylaxis (GlobeNewswire) +6.26%
Sep-04-25 02:54PM	ARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDA (Insider Monkey)
Aug-28-25 08:00AM	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-25 08:15AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -5.04%
07:00AM	ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy (epinephrine nasal spray) (GlobeNewswire)
05:26AM	Cisco Systems headlines earnings slate (MarketWatch)
Aug-12-25 09:24AM	ARS Pharmaceuticals Inc (SPRY) Q2 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Aug-11-25 06:55PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -6.40%
Aug-08-25 01:56PM	Paramount, Rocket, and More Stocks See Action From Activist Investors (Barrons.com)
Aug-04-25 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 05:35PM	Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates (Zacks)
08:50AM	Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength (Zacks)
Jul-30-25 10:00AM	Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
10:00AM	Loading…
Jul-29-25 10:00AM	Analysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-18-25 12:27PM	MHRA approves needle-free adrenaline nasal spray for anaphylaxis (Pharmaceutical Technology)
09:25AM	EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)
Jul-15-25 12:00PM	ARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy? (Zacks)
09:55AM	Wall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High? (Zacks)
08:50AM	What Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing' (Zacks)
Jun-15-25 05:26AM	Jim Cramer on ARS Pharmaceuticals: "It's a Great Flier" (Insider Monkey)
Jun-11-25 09:02PM	Lightning Round: I don't want to buy enterprise software right now, says Jim Cramer (CNBC TV)
May-27-25 08:00AM	ARS Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-15-25 03:12AM	ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Call Highlights: Strong Launch of Neffy Amid ... (GuruFocus.com)
May-14-25 10:44PM	Q1 2025 ARS Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -9.36%
08:15AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy (epinephrine nasal spray) (GlobeNewswire)
May-13-25 09:28AM	ARS Pharmaceuticals Inc (SPRY) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
May-08-25 05:06AM	ARS Pharmas epinephrine nasal spray 1mg now available in US (Pharmaceutical Technology)
May-05-25 08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results (GlobeNewswire)
May-04-25 04:32PM	Aquestive Therapeutics: Unprofitable For A Few More Years, But Significant Upside Potential (Seeking Alpha)
May-02-25 08:00AM	ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abello A/S to Expand Reach of neffy (epinephrine nasal spray) to Additional U.S. Pediatricians (GlobeNewswire)
Apr-30-25 06:51AM	ARS Pharmaceuticals Has A Blockbuster Candidate (Seeking Alpha)
Apr-05-25 05:31PM	ARS Pharmaceuticals (SPRY): Among Unstoppable Stocks That Could Double Your Money (Insider Monkey)
Mar-23-25 07:18AM	Wall Street Week Ahead (SeekingAlpha)
Mar-21-25 12:16PM	Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz (TipRanks) -13.63%
12:03PM	ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
03:03AM	ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
12:40AM	Q4 2024 ARS Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-25 04:04PM	ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. (Investor's Business Daily) +22.83%
03:31PM	ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await (SeekingAlpha)
01:29PM	ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion (SeekingAlpha)
01:28PM	ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript (SeekingAlpha)
08:25AM	ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates (Zacks)
07:00AM	ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-06-25 05:27AM	FDA approves ARS neffy 1mg for paediatric anaphylaxis (Pharmaceutical Technology)
Mar-03-25 04:35PM	ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences (GlobeNewswire)
Feb-20-25 07:02PM	ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients (GlobeNewswire)
Feb-18-25 08:00AM	ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting (GlobeNewswire)
Feb-05-25 08:00AM	ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference (GlobeNewswire)
Jan-21-25 08:00AM	ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools (GlobeNewswire) +7.24%
Jan-13-25 04:15PM	BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. (Investor's Business Daily)
08:00AM	ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy (epinephrine nasal spray) (GlobeNewswire)
Jan-07-25 08:15AM	ARS Pharmaceuticals files for approval of neffy in Canada, U.K. (TipRanks)
06:43AM	ARS Pharma seeks approval for epinephrine spray in Canada and UK (Medical Device Network)
Jan-06-25 08:00AM	ARS Pharmaceuticals Files for Approval of neffy in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abello A/S (GlobeNewswire)
08:00AM	ARS Pharmaceuticals Files for Approval of neffy in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abell A/S (GlobeNewswire)
Dec-19-24 05:25PM	ARS Pharmaceuticals Announces neffy (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies (GlobeNewswire)
Dec-18-24 08:00AM	ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.80%
Dec-12-24 02:32PM	ARS Pharmaceuticals Announces Filings for Approval of neffy in China, Japan and Australia (GlobeNewswire)
Dec-04-24 08:00AM	ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost (GlobeNewswire) +5.95%
Nov-14-24 02:08AM	ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ... (GuruFocus.com)
Nov-13-24 07:40AM	ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -15.23%
06:30AM	ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-12-24 07:06AM	ARS Pharmaceuticals announces agreement with ALK to commercialize neffy (TipRanks) -5.03%
Nov-11-24 04:02PM	ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray (Investor's Business Daily)
11:01AM	ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m (Pharmaceutical Technology)
07:41AM	ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 (Benzinga)
07:00AM	ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy in Europe, Canada and Other Geographies Outside the United States (GlobeNewswire)
Nov-09-24 05:30PM	ALK licenses rights to neffy , the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis) (GlobeNewswire)
Nov-06-24 09:55AM	Wall Street Analysts Think ARS Pharmaceuticals, Inc. (SPRY) Could Surge 67.56%: Read This Before Placing a Bet (Zacks)
08:00AM	ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences (GlobeNewswire)
Oct-24-24 08:30AM	ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting (GlobeNewswire)
Oct-14-24 09:55AM	Wall Street Analysts Believe ARS Pharmaceuticals, Inc. (SPRY) Could Rally 76.79%: Here's is How to Trade (Zacks)
Sep-30-24 10:33AM	Neffy nasal spray: a game changer for asthma patients and epinephrine delivery? (Pharmaceutical Technology)
Sep-23-24 08:00AM	ARS Pharmaceuticals Announces U.S. Availability of neffy (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis (GlobeNewswire)
Sep-11-24 08:20AM	ARS Pharmaceuticals (SPRY): A Bull Case Theory (Insider Monkey)
Sep-10-24 04:05PM	ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-09-24 04:47PM	ARS Pharmaceuticals Submits sNDA to FDA for neffy 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.) (GlobeNewswire)
Sep-06-24 12:00PM	ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's Why (Zacks)
Sep-04-24 08:00AM	ARS Pharmaceuticals Launches Pre-Ordering Services for neffy to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis (GlobeNewswire)
Aug-27-24 10:08AM	Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned (UPDATED) (Benzinga) +5.76%
Aug-26-24 09:29AM	EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) (GlobeNewswire)

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. Its product includes Epinephrine Nasal Spray. The company was founded by Richard Lowenthal, Robert Bell, and Sarina Tanimoto on August 5, 2015 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dorsey Brian	Chief Operating Officer	Nov 13 '25	Option Exercise	0.64	21,828	13,970	32,617	Nov 14 06:43 PM
Dorsey Brian	Chief Operating Officer	Nov 13 '25	Sale	8.71	21,828	190,050	10,789	Nov 14 06:43 PM
Chakma Justin	Chief Business Officer	Nov 12 '25	Option Exercise	0.84	30,000	25,200	166,380	Nov 14 06:42 PM
Chakma Justin	Chief Business Officer	Nov 12 '25	Sale	8.87	166,380	1,476,147	0	Nov 14 06:42 PM
BRIAN T DORSEY	Officer	Nov 13 '25	Proposed Sale	8.71	21,828	190,050		Nov 13 04:08 PM
JUSTIN CHAKMA	Officer	Nov 12 '25	Proposed Sale	8.91	30,000	267,357		Nov 12 05:26 PM
Chakma Justin	Officer	Nov 12 '25	Proposed Sale	8.87	138,380	1,227,420		Nov 12 10:56 AM
Lowenthal Richard E	PRESIDENT AND CEO	Aug 21 '25	Sale	14.49	50,000	724,345	1,196,494	Aug 22 04:30 PM
Scott Kathleen D.	Chief Financial Officer	Aug 21 '25	Option Exercise	1.50	12,500	18,750	22,542	Aug 22 04:30 PM
Scott Kathleen D.	Chief Financial Officer	Aug 21 '25	Sale	15.00	12,500	187,500	10,042	Aug 22 04:30 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Aug 20 '25	Sale	14.09	37,656	530,626	1,247,447	Aug 21 05:36 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Aug 19 '25	Sale	14.03	12,344	173,130	1,285,103	Aug 21 05:36 PM
KATHLEEN D SCOTT	Officer	Aug 21 '25	Proposed Sale	15.00	12,500	187,500		Aug 21 04:18 PM
Lowenthal Richard E	Officer	Aug 21 '25	Proposed Sale	14.15	150,000	2,123,000		Aug 21 11:20 AM
Tanimoto Sarina	Officer	Aug 19 '25	Proposed Sale	14.00	150,000	2,100,000		Aug 19 10:22 AM
Karas Eric	Chief Commercial Officer	Jul 01 '25	Option Exercise	1.50	15,000	22,500	25,315	Jul 03 04:21 PM
Karas Eric	Chief Commercial Officer	Jul 01 '25	Sale	16.99	15,000	254,860	10,315	Jul 03 04:21 PM
Flynn James E	10% Owner	Jun 27 '25	Sale	18.46	740,149	13,663,151	4,887,254	Jul 01 04:42 PM
ERIC KARAS	Officer	Jul 01 '25	Proposed Sale	16.99	15,000	254,859		Jul 01 04:20 PM
Karas Eric	Chief Commercial Officer	Jun 18 '25	Option Exercise	1.50	15,000	22,500	22,696	Jun 20 06:38 PM
Karas Eric	Chief Commercial Officer	Jun 18 '25	Sale	16.00	15,000	240,000	7,696	Jun 20 06:38 PM
ERIC KARAS	Officer	Jun 18 '25	Proposed Sale	16.00	15,000	240,000		Jun 18 04:51 PM
Fitzpatrick Alexander A	Chief Legal Officer	May 20 '25	Option Exercise	5.58	100,000	558,000	192,582	May 22 05:00 PM
Fitzpatrick Alexander A	Chief Legal Officer	May 20 '25	Sale	14.10	102,969	1,451,513	89,613	May 22 05:00 PM
SAUNDERS BRENT L	Director	May 20 '25	Option Exercise	1.01	120,000	121,200	120,000	May 22 05:00 PM
SAUNDERS BRENT L	Director	May 20 '25	Sale	14.25	120,000	1,710,024	0	May 22 05:00 PM
Scott Kathleen D.	Chief Financial Officer	May 20 '25	Option Exercise	1.50	50,000	75,000	57,424	May 22 05:00 PM
Scott Kathleen D.	Chief Financial Officer	May 20 '25	Sale	14.10	50,000	705,165	7,424	May 22 05:00 PM
Scott Kathleen D.	Officer	May 20 '25	Proposed Sale	14.10	50,000	705,000		May 20 05:24 PM
Fitzpatrick Alexander A	Officer	May 20 '25	Proposed Sale	14.02	102,969	1,443,894		May 20 04:50 PM
SAUNDERS BRENT L	Director	May 20 '25	Proposed Sale	14.25	120,000	1,710,000		May 20 04:48 PM
Shawver Laura	Director	Apr 07 '25	Option Exercise	4.85	50,002	242,510	260,348	Apr 08 04:45 PM
Shawver Laura	Director	Apr 07 '25	Sale	12.30	50,002	615,075	210,346	Apr 08 04:45 PM
Shawver Laura	Director	Apr 07 '25	Proposed Sale	12.30	50,002	615,051		Apr 07 02:26 PM
Karas Eric	Chief Commercial Officer	Mar 20 '25	Option Exercise	1.50	10,000	15,000	17,696	Mar 21 06:30 PM
Karas Eric	Chief Commercial Officer	Mar 20 '25	Sale	14.00	10,000	140,000	7,696	Mar 21 06:30 PM
ERIC KARAS	Officer	Mar 20 '25	Proposed Sale	14.00	10,000	140,000		Mar 20 04:03 PM
Shawver Laura	Director	Mar 06 '25	Option Exercise	4.85	49,600	240,560	259,946	Mar 07 05:12 PM
Shawver Laura	Director	Mar 05 '25	Option Exercise	4.85	400	1,940	210,746	Mar 07 05:12 PM
Shawver Laura	Director	Mar 06 '25	Sale	11.21	49,600	556,046	210,346	Mar 07 05:12 PM
Shawver Laura	Director	Mar 05 '25	Sale	11.00	400	4,400	210,346	Mar 07 05:12 PM
Shawver Laura	Director	Mar 05 '25	Proposed Sale	11.00	50,000	550,000		Mar 05 05:19 PM
Shawver Laura	Director	Feb 03 '25	Option Exercise	4.54	50,000	227,091	260,346	Feb 04 04:35 PM
Shawver Laura	Director	Feb 03 '25	Sale	12.31	50,000	615,565	210,346	Feb 04 04:35 PM
Shawver Laura	Director	Feb 03 '25	Proposed Sale	12.31	50,000	615,565		Feb 03 12:06 PM
Shawver Laura	Director	Jan 06 '25	Option Exercise	3.15	50,000	157,500	260,346	Jan 07 06:24 PM
Shawver Laura	Director	Jan 06 '25	Sale	11.10	50,000	555,065	210,346	Jan 07 06:24 PM
Shawver Laura	Director	Jan 06 '25	Proposed Sale	11.10	50,000	555,065		Jan 06 04:36 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 17 '24	Sale	11.67	100,000	1,167,100	1,098,499	Dec 19 04:20 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 17 '24	Sale	11.67	100,000	1,167,100	1,098,499	Dec 19 04:20 PM
Chakma Justin	Chief Business Officer	Dec 12 '24	Option Exercise	0.84	117,333	98,560	253,713	Dec 13 07:53 PM
Chakma Justin	Chief Business Officer	Dec 13 '24	Option Exercise	1.44	27,272	39,272	163,652	Dec 13 07:53 PM
Chakma Justin	Chief Business Officer	Dec 12 '24	Sale	12.27	117,333	1,439,124	136,380	Dec 13 07:53 PM
Chakma Justin	Chief Business Officer	Dec 13 '24	Sale	12.06	27,272	328,968	136,380	Dec 13 07:53 PM
Dorsey Brian	Chief Operating Officer	Dec 12 '24	Option Exercise	0.64	25,000	16,000	31,024	Dec 13 07:52 PM
Dorsey Brian	Chief Operating Officer	Dec 11 '24	Option Exercise	0.64	15,000	9,600	21,024	Dec 13 07:52 PM
Dorsey Brian	Chief Operating Officer	Dec 12 '24	Sale	12.30	25,000	307,432	6,024	Dec 13 07:52 PM
Dorsey Brian	Chief Operating Officer	Dec 11 '24	Sale	12.43	15,000	186,426	6,024	Dec 13 07:52 PM
Chakma Justin	Officer	Dec 13 '24	Proposed Sale	12.06	27,272	328,967		Dec 13 05:24 PM
Chakma Justin	Chief Business Officer	Dec 10 '24	Option Exercise	0.84	50,000	42,000	186,380	Dec 12 05:41 PM
Chakma Justin	Chief Business Officer	Dec 10 '24	Sale	13.15	50,000	657,625	136,380	Dec 12 05:41 PM
Chakma Justin	Officer	Dec 10 '24	Proposed Sale	11.50	117,333	1,349,330		Dec 12 05:02 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 10 '24	Sale	13.16	100,000	1,316,420	1,148,499	Dec 11 06:30 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 10 '24	Sale	13.16	100,000	1,316,420	1,148,499	Dec 11 06:30 PM
Dorsey Brian	Officer	Dec 11 '24	Proposed Sale	13.31	61,200	814,572		Dec 11 05:31 PM
Chakma Justin	Director	Dec 10 '24	Proposed Sale	14.02	50,000	701,000		Dec 10 04:48 PM
Lowenthal Richard E	Officer	Dec 10 '24	Proposed Sale	13.40	300,000	4,020,000		Dec 10 11:15 AM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 06 '24	Option Exercise	4.67	25,665	119,852	3,433,512	Dec 09 05:43 PM
Tanimoto Sarina	CHIEF MEDICAL OFFICER	Dec 06 '24	Option Exercise	8.42	11,876	99,996	4,327,189	Dec 09 05:43 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 06 '24	Option Exercise	4.67	25,665	119,852	3,433,512	Dec 09 05:25 PM
Lowenthal Richard E	PRESIDENT AND CEO	Dec 06 '24	Option Exercise	8.42	11,876	99,996	4,327,189	Dec 09 05:25 PM
Chakma Justin	Chief Business Officer	Dec 06 '24	Option Exercise	0.84	50,000	42,000	186,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 05 '24	Option Exercise	0.84	49,640	41,698	186,020	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 04 '24	Option Exercise	0.84	45,000	37,800	181,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 06 '24	Sale	14.23	50,000	711,615	136,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 05 '24	Sale	14.13	49,640	701,642	136,380	Dec 06 07:15 PM
Chakma Justin	Chief Business Officer	Dec 04 '24	Sale	13.95	45,000	627,944	136,380	Dec 06 07:15 PM
Chakma Justin	Officer	Dec 06 '24	Proposed Sale	14.00	50,000	700,000		Dec 06 05:30 PM
Chakma Justin	Officer	Dec 05 '24	Proposed Sale	13.32	49,640	661,205		Dec 05 05:06 PM
Chakma Justin	Chief Business Officer	Dec 02 '24	Option Exercise	0.84	45,000	37,800	181,380	Dec 04 09:45 PM
Chakma Justin	Chief Business Officer	Dec 03 '24	Option Exercise	0.84	45,000	37,800	181,380	Dec 04 09:45 PM
Chakma Justin	Chief Business Officer	Dec 02 '24	Sale	13.67	45,000	615,218	136,380	Dec 04 09:45 PM
Chakma Justin	Chief Business Officer	Dec 03 '24	Sale	13.19	45,000	593,402	136,380	Dec 04 09:45 PM
Shawver Laura	Director	Dec 03 '24	Option Exercise	2.60	87,984	229,010	298,330	Dec 04 09:40 PM
Shawver Laura	Director	Dec 02 '24	Option Exercise	1.27	97,244	123,500	307,590	Dec 04 09:40 PM
Shawver Laura	Director	Dec 04 '24	Option Exercise	3.15	14,772	46,532	225,118	Dec 04 09:40 PM
Shawver Laura	Director	Dec 02 '24	Sale	13.56	97,244	1,318,745	210,346	Dec 04 09:40 PM
Shawver Laura	Director	Dec 03 '24	Sale	13.26	87,984	1,166,897	210,346	Dec 04 09:40 PM
Shawver Laura	Director	Dec 04 '24	Sale	13.75	14,772	203,109	210,346	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 04 '24	Option Exercise	1.50	6,283	9,424	11,976	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 02 '24	Option Exercise	1.50	3,717	5,576	9,410	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 04 '24	Sale	14.00	6,283	87,962	5,693	Dec 04 09:40 PM
Karas Eric	Chief Commercial Officer	Dec 02 '24	Sale	14.11	3,717	52,461	5,693	Dec 04 09:40 PM
ERIC KARAS	Officer	Dec 04 '24	Proposed Sale	14.00	6,283	87,962		Dec 04 05:46 PM
Chakma Justin	Officer	Dec 04 '24	Proposed Sale	14.51	45,000	652,950		Dec 04 05:15 PM
Chakma Justin	Officer	Dec 03 '24	Proposed Sale	13.00	45,000	585,000		Dec 03 05:25 PM
Chakma Justin	Officer	Dec 02 '24	Proposed Sale	14.51	45,000	652,950		Dec 02 07:01 PM
Shawver Laura	Director	Dec 02 '24	Proposed Sale	13.56	200,000	2,713,000		Dec 02 06:22 PM
ERIC KARAS	Officer	Dec 02 '24	Proposed Sale	14.11	3,717	52,461		Dec 02 04:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

SPRY

ARS Pharmaceuticals Inc

Upgrade your FINVIZ experience